Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)
- 30 October 2003
- journal article
- clinical trial
- Published by Springer Nature in Leukemia
- Vol. 18 (1) , 133-138
Abstract
Several trials have shown the superior impact of high-dose melphalan (usually 200 mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100 mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum β2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (PP=0.08). Median event-free survival (EFS) was 32 months in the MEL100 group and 42 months in the MEL200 group (P<0.005), but overall survival (OS) was not different. Transplant-related mortality was not significantly different. Haematological and extra-haematological toxicity was significantly reduced after MEL100. Despite the significant age difference, tandem MEL100 was less toxic than tandem MEL200, and MEL100 was inferior to MEL200 in terms of EFS but not in terms of OS. The intensified nonmyeloablative MEL100 regimen is an effective first-line treatment.Keywords
This publication has 24 references indexed in Scilit:
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myelomaLeukemia, 2002
- The Role of High-Dose Chemotherapy and Stem-Cell Transplantation in Patients with Multiple Myeloma: A Practice Guideline of the Cancer Care Ontario Practice Guidelines InitiativeAnnals of Internal Medicine, 2002
- Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trialBlood, 2002
- Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish RegistryBone Marrow Transplantation, 1998
- Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patientsBone Marrow Transplantation, 1997
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.Journal of Clinical Oncology, 1992
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958